Status:

RECRUITING

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Lead Sponsor:

Mamta Parikh

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Advanced Prostate Adenocarcinoma

Stage III Prostate Cancer AJCC v8

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

This phase II trial compares the effects, good and/or bad of abiraterone and prednisone or darolutamide alone in treating patients with prostate cancer that may have spread from where it first started...

Detailed Description

PRIMARY OBJECTIVE: I. Tolerability. SECONDARY OBJECTIVES: I. Tolerability in prespecified subpopulations. II. Prostate-specific antigen (PSA) response at 7 months. OUTLINE: Patients are assigned ...

Eligibility Criteria

Inclusion

  • Ability to understand and willingness to sign an informed consent form
  • Histologically confirmed prostate adenocarcinoma
  • Advanced prostate cancer appropriate for treatment with abiraterone acetate plus prednisone or darolutamide as assessed by the treating physician
  • Participants are encouraged to be currently treated with androgen deprivation therapy (ADT) or having undergone bilateral orchiectomy
  • Performance status 0 - 2 (Karnofsky ≥ 50%)
  • Age ≥ 18 years at time of consent
  • Life expectancy ≥ 6 months per investigator discretion
  • Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study

Exclusion

  • Have been on either abiraterone or darolutamide for \> 28 days prior to initiating enrollment
  • Any condition that in the opinion of the investigator would prohibit the understanding or rendering of informed consent or interfere with the participant's safety or compliance while on trial

Key Trial Info

Start Date :

November 9 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2027

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT06173362

Start Date

November 9 2023

End Date

May 1 2027

Last Update

December 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California Davis Comprehensive Cancer Center

Sacramento, California, United States, 95817